The Center for Chronic Lymphocytic Leukemia (CLL) is part of the Hematologic Oncology (Blood Cancers) Treatment Center at Dana-Farber/Brigham and Women's Cancer Center. Our program promotes a comprehensive approach to the treatment of patients with CLL and provides a centralized hub for CLL research.
The Center for Chronic Lymphocytic Leukemia (CLL) provides care for patients with chronic lymphocytic leukemia (CLL), and offers access to clinical trials of exciting new drugs, as well as extensive prognostic testing, tissue banking and stem cell transplantation for CLL.
Patients may access a comprehensive range of services specialized for CLL treatment, including:
From the time of diagnosis, Dana-Farber offers a personalized CLL risk-assessment, which provides detailed, patient-specific information about an individual's disease and prognosis. Our CLL-focused physicians then work with patients to use this information in planning and implementing treatment strategies. We offer patients with CLL specialized clinical trials, which give patients the opportunity to receive novel therapies on clinical trials. Our ultimate research goal is to improve current therapies to benefit all patients.
The Center for Chronic Lymphocytic Leukemia (CLL) treatment team includes physicians and clinicians with extensive experience caring for patients with CLL.
Jennifer R. Brown, MD, PhD, DirectorMatthew Davids, MD, MMScDavid Frank, MD, PhD
Jeffrey Hellman, PA-CKaren Francoeur, BSN, RN
Our Lymphoma Program physicians treat patients with all types of lymphoma. We work closely with our transplant service team when CLL patients require bone marrow/stem cell transplantation.
Patients have the opportunity to participate in trials for new therapies for all phases of Chronic Lymphocytic Leukemia (CLL), including advanced CLL. These trials include:
Learn more about clinical trials for CLL patients.
Translational science, which quickly moves laboratory findings into clinical practice, is also a key focus of the Center for Chronic Lymphocytic Leukemia. This includes:
Dana-Farber is currently enrolling participants for a Genetic Study of Familial Chronic Lymphocytic Lymphoma. This study, led by Jennifer R. Brown, MD, PhD, seeks to identify the genes that cause the disease, in order to develop methods of prevention and diagnosis counseling. To be eligible, participants must have at least two first-degree relatives (e.g., parent, sibling, or child) who have a lymphoma or lymphoproliferative disorder. For more information, including detailed eligibility guidelines and participation requirements, contact lead investigator Jennifer R Brown, MD, PhD or study coordinator Alexander Vartanov.
Learn more about the Harvard Study of Genetic Factors that Lead to Lymphoma
Chronic Lymphocytic Leukemia patients may call 617-632-6246 or 617-632-5138, or use this online form to make an appointment.
You may schedule your first appointment for as soon as the next day. After scheduling, one of our nurses will call you to answer your questions and help you prepare for the appointment.
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Hematologic Malignancies DivisionDana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: